Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). BPC-157 is a synthetic peptide that has demonstrated promising regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but it has not yet been studied in formal human clinical trials.
Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. Participants will self-administer subcutaneous injections daily for 90 days following surgery. All other aspects of care will follow the standard postoperative rehabilitation protocol.
The study will assess tendon healing using postoperative MRI, patient-reported outcome measures (PROMs), range of motion (ROM), and muscle strength via handheld dynamometry. Blood samples will also be collected to evaluate biomarkers associated with collagen turnover and inflammation.
The goal of this pilot study is to evaluate the safety, feasibility, and preliminary efficacy of BPC-157 in promoting tendon healing and improving functional outcomes after rotator cuff repair. Results will inform the design of a future larger-scale clinical trial.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences Medical Center
-
Kontakt:
- Shiloah Kviatkovsky
- Telefonnummer: 619-677-0792
- E-Mail: skviatkovsky@uams.edu
-
Hauptermittler:
- Shiloah Kviatkovsky, P.h.D.
-
Unterermittler:
- Ryan Hill, M.D.
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Males and Females, 18 years old or older
- Body mass index of 20.0 to 34.9 kg/m2
- Pre-operative MRI demonstrating a full thickness tear of the posterosuperior rotator cuff less than 2.5 cm in anteroposterior dimension
- Scheduled for an aRCR at UAMS with Dr. Ryan Hill, Dr. Paul Inclan, or Dr. Justin Rabinowitz
- COVID-19 negative and/or asymptomatic
Exclusion Criteria:
- Previous RCR
- Pregnant or breastfeeding status
- Current drug and alcohol abuse · History of platelet-rich plasma injection, other platelet-based product or biologic injection in the past 12 months in the ipsilateral shoulder
- Lack of decisional capacity
- Having undergone hormone replacement therapy in the last 12 months
- Having undergone testosterone replacement therapy in the last 12 months
- Active diagnosis of blood borne infectious disease
- Diabetic
- Documented history or diagnosis of autoimmune disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: BPC-157 Group
Participants in this arm will receive BPC-157.
BPC-157 will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice.
It has demonstrated pro-angiogenic, cytoprotective, and tissue-regenerative effects in multiple preclinical models of musculoskeletal injury, including tendon and ligament healing.
Although widely discussed in experimental and anecdotal contexts, BPC-157 has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA.
This study is designed to explore its potential role in promoting tendon regeneration and functional recovery in a postoperative orthopaedic setting.
|
|
Schein-Komparator: Sham
Participants in this arm will receive normal saline.
Normal saline will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
Participants in this group will not receive any active treatment or placebo injections.
This sham group serves as a no-treatment control to evaluate the natural course of postoperative recovery following arthroscopic rotator cuff repair without investigational intervention.
Participants will continue to receive standard postoperative care and rehabilitation in accordance with institutional protocols.
This group is included to help differentiate the effects of BPC-157 from both placebo and routine recovery.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Shoulder Strength
Zeitfenster: Baseline, 12 weeks, and 5 months post operatively
|
Isometric shoulder abduction strength will be assessed using a handheld dynamometer.
Strength measurements will focus on shoulder abduction and external rotation at 0° abduction.
Three trials will be recorded, and the average peak force will be used as the outcome value.
Testing will be performed by a blinded evaluator using a standardized protocol.
|
Baseline, 12 weeks, and 5 months post operatively
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 298969
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .